01. Ongoing Clinical Trials
Ongoing Mesothelioma Clinical Trials
Clinical trials are designed to test new treatments as efficiently as possible. Part of this design means only a certain number of patients can be accepted into each study. Once a mesothelioma study reaches this enrollment target, no additional mesothelioma patients are accepted. The study is still considered to be ongoing, as doctors continue treating and monitoring existing study patients.
Some clinical trials release preliminary study results during this time period. For instance, the CheckMate 743 clinical trial did this in 2020. CheckMate 743 investigated the use of two immunotherapy drugs compared to standard chemotherapy treatment.
The immunotherapy drug combination (nivolumab and ipilimumab) performed better than standard chemotherapy. Patients treated with the immunotherapy drugs lived about four months longer than those receiving chemotherapy.
After reviewing the study results, the U.S. Food and Drug Administration (FDA) approved the immunotherapy drugs. Specifically, nivolumab and ipilimumab were approved for the treatment of inoperable pleural mesothelioma.
If you or a loved one are considering enrolling in a clinical trial, you can find open studies on our Clinical Trials – Recruiting page.
02. List of Ongoing Clinical Trials
Ongoing Mesothelioma Clinical Trials Not Recruiting Patients
Provided below is a list of mesothelioma trials that are no longer accepting new patients.
Note: The information below is provided by ClinicalTrials.gov.
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
Conditions:
Last Updated: January 27, 2022
Status: Active, not recruiting
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: January 27, 2022
Status: Active, not recruiting
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: January 25, 2022
Status: Active, not recruiting
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Conditions: Mesothelioma
Last Updated: January 24, 2022
Status: Active, not recruiting
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: January 22, 2022
Status: Active, not recruiting
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: January 21, 2022
Status: Active, not recruiting
Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
Conditions: Mesothelioma
Last Updated: January 19, 2022
Status: Active, not recruiting
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
Conditions: Mesothelioma
Last Updated: January 18, 2022
Status: Active, not recruiting
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Conditions: Mesothelioma
Last Updated: January 15, 2022
Status: Active, not recruiting
First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin
Conditions: Mesothelioma
Last Updated: January 11, 2022
Status: Active, not recruiting
The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance
Conditions: Mesothelioma
Last Updated: January 11, 2022
Status: Active, not recruiting
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: January 6, 2022
Status: Active, not recruiting
A Study of LY3023414 in Participants With Advanced Cancer
Conditions: Mesothelioma
Last Updated: January 5, 2022
Status: Active, not recruiting
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
Conditions: Mesothelioma
Last Updated: December 23, 2021
Status: Active, not recruiting
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Conditions: Mesothelioma
Last Updated: December 22, 2021
Status: Active, not recruiting
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Conditions:
Last Updated: December 21, 2021
Status: Active, not recruiting
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study
Conditions: Mesothelioma
Last Updated: December 8, 2021
Status: Active, not recruiting
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: November 30, 2021
Status: Active, not recruiting
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Conditions: Mesothelioma
Last Updated: November 10, 2021
Status: Active, not recruiting
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma
Conditions: Mesothelioma
Last Updated: November 6, 2021
Status: Active, not recruiting
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Conditions: Mesothelioma
Last Updated: October 29, 2021
Status: Active, not recruiting
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: October 25, 2021
Status: Active, not recruiting
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: October 20, 2021
Status: Active, not recruiting
Phase I Trial HIPEC With Nal-irinotecan
Conditions: Mesothelioma
Last Updated: October 19, 2021
Status: Active, not recruiting
Pembrolizumab in Treating Patients With Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: October 8, 2021
Status: Active, not recruiting
A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia
Conditions: Mesothelioma
Last Updated: September 30, 2021
Status: Active, not recruiting
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
Conditions: Mesothelioma
Last Updated: September 29, 2021
Status: Active, not recruiting
Intrapleural Cryotherapy for Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: September 14, 2021
Status: Active, not recruiting
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
Conditions: Mesothelioma
Last Updated: September 13, 2021
Status: Active, not recruiting
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
Conditions: Mesothelioma
Last Updated: September 10, 2021
Status: Active, not recruiting
A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)
Conditions: Mesothelioma
Last Updated: September 8, 2021
Status: Active, not recruiting
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Conditions:
Last Updated: August 10, 2021
Status: Active, not recruiting
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Conditions:
Last Updated: July 29, 2021
Status: Active, not recruiting
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: June 15, 2021
Status: Active, not recruiting
Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: June 11, 2021
Status: Active, not recruiting
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma
Conditions: Mesothelioma
Last Updated: May 10, 2021
Status: Active, not recruiting
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
Conditions:
Last Updated: May 3, 2021
Status: Active, not recruiting
TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
Conditions: Mesothelioma
Last Updated: April 11, 2021
Status: Active, not recruiting
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Conditions: Mesothelioma
Last Updated: March 24, 2021
Status: Active, not recruiting
Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma
Conditions: Mesothelioma
Last Updated: March 4, 2021
Status: Active, not recruiting
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: February 8, 2021
Status: Active, not recruiting
A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: October 6, 2020
Status: Active, not recruiting
A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM
Conditions: Mesothelioma
Last Updated: July 29, 2020
Status: Active, not recruiting
Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134
Conditions: Mesothelioma
Last Updated: May 9, 2019
Status: Active, not recruiting
